Human ipsc-derived cardiomyocyte model for inherited cardiomyopathy

Overview

The development of a human disease model utilizing induced pluripotent stem cells (iPSCs) derived from patients with various forms of inherited cardiomyopathy offers a groundbreaking approach to understanding and treating these complex conditions. This research focuses on generating iPSC-derived cardiomyocytes to recapitulate the disease state, providing a platform for testing upstream therapies targeting the molecular basis of inherited cardiomyopathies. This model is invaluable for advancing diagnostics and therapeutic strategies for intractable cardiovascular diseases, including advanced heart failure.

Technical specifications

• iPSC Generation: iPSCs have been created from patients with different types of cardiomyopathy, including DCM, HCM, end-stage HCM, and ARVC, ensuring a comprehensive model.
• Validation: These iPSCs have confirmed normal karyotypes and express pluripotent markers, validating their potential to differentiate into cardiomyocytes.
• Pathogenic Variants: The model includes cells carrying various pathogenic variants, such as LMNA, which are critical for studying the disease mechanisms.
• Resource Sharing: iPSCs are deposited at the RIKEN bioresource research center for collaborative research opportunities.

Technology readiness level

This technology is at TRL 3, indicating that it has been validated in a laboratory setting. The iPSCs have been characterized and are ready for further development and application in collaborative research settings to enhance therapeutic development.